4BIO Capital – Weekly Recap

4BIO Capital is a specialist life sciences investor focused on advanced therapies, and this weekly recap highlights notable portfolio developments over the past week. The period was dominated by news from Ray Therapeutics, an optogenetics-focused ophthalmology company in which 4BIO is a founding investor.

Ray Therapeutics closed an upsized, oversubscribed $125 million Series B financing to advance its optogenetic vision restoration platform. The round follows the recent U.S. FDA Regenerative Medicine Advanced Therapy designation for lead candidate RTx-015 in retinitis pigmentosa, signaling increasing clinical and regulatory momentum.

Proceeds from the Series B are expected to fund two clinical-stage programs: RTx-015 for retinitis pigmentosa and RTx-021 targeting macular diseases, including Stargardt disease and geographic atrophy age-related macular degeneration. This expands Ray’s potential to address multiple severe retinal conditions from a single platform, enhancing its strategic value within 4BIO’s portfolio.

4BIO Capital’s role has been reinforced as it led Ray’s seed round in 2021, participated in the Series A in 2023, and has again joined the Series B. Managing Partner Dima Kuzmin sits on Ray’s board, underscoring 4BIO’s active involvement in guiding regulatory strategy and scaling the company’s differentiated optogenetic approach.

The oversubscribed nature of the financing and participation from major global institutions suggest strong external validation of Ray Therapeutics’ technology and development path. For 4BIO, this materially de-risks the near- to mid-term clinical and regulatory roadmap for a key asset, while concentrating exposure around outcomes in high-need retinal indications.

From a portfolio perspective, these developments strengthen 4BIO Capital’s position in ophthalmology gene therapy and advanced vision restoration therapies. Overall, the week marked a positive step for 4BIO Capital, with increased visibility and institutional backing around one of its flagship portfolio companies and clearer funding runway for critical clinical milestones.